• Explore /
  • Poster
  • / A randomized phase Ib/II study of niraparib (nira) plus nivolumab (nivo) or ipilimumab (ipi) in patients (pts) with platinum-sensitive advanced pancreatic cancer (aPDAC).

A randomized phase Ib/II study of niraparib (nira) plus nivolumab (nivo) or ipilimumab (ipi) in patients (pts) with platinum-sensitive advanced pancreatic cancer (aPDAC).

Abstract Poster

Authors

null

Kim Anna Reiss

University of Pennsylvania Abramson Cancer Center, Philadelphia, PA

Kim Anna Reiss , Rosemarie Mick , Ursina R. Teitelbaum , Mark H. O'Hara , Charles John Schneider , Ryan Campbell Massa , Thomas Benjamin Karasic , Chioma Onyiah , Mary Kate Gosselin , Alyssa Donze , Susan M. Domchek , Robert H. Vonderheide

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT03404960

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4021)

DOI

10.1200/JCO.2022.40.16_suppl.4021

Abstract #

4021

Poster Bd #

9

Abstract Disclosures

Similar Posters

First Author: Kim Anna Reiss

First Author: Lorenzo Pilla

First Author: Martin Reck

First Author: Kohei Shitara